Hemogenyx Pharmaceuticals (LSE:HEMO) EV-to-EBIT : -3.55 (As of May. 15, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Hemogenyx Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hemogenyx Pharmaceuticals's Enterprise Value is £22.63 Mil. Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.38 Mil. Therefore, Hemogenyx Pharmaceuticals's EV-to-EBIT for today is -3.55.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

LSE:HEMO' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.39 Med: 0 Max: 0
Current: -3.55

LSE:HEMO's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs LSE:HEMO: -3.55

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hemogenyx Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was £28.70 Mil. Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.38 Mil. Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -22.23%.

Hemogenyx Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals EV-to-EBIT Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-5.35

-20.20

-4.58

-3.47

-4.50

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial												-4.58	-	-3.47	-	-4.50

Competitive Comparison of Hemogenyx Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's EV-to-EBIT falls into.

Hemogenyx Pharmaceuticals EV-to-EBIT Calculation

Hemogenyx Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	22.631	/	-6.381
	=	-3.55

Hemogenyx Pharmaceuticals's current Enterprise Value is £22.63 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.38 Mil.

Hemogenyx Pharmaceuticals (LSE:HEMO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hemogenyx Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-6.381	/	28.69811
	=	-22.23 %

Hemogenyx Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was £28.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hemogenyx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.38 Mil.

Hemogenyx Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (LSE:HEMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (LSE:HEMO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (LSE:HEMO) Headlines

No Headlines